Bosentan in pulmonary arterial hypertension: a comparison between congenital heart disease and chronic pulmonary embolism
暂无分享,去创建一个
B. Mulder | M. Groenink | B. Bouma | P. Bresser | M. Winter | E. Hoendermis | R. Berger | M. Duffels | A. Dijk | S. Surie | M. N. Plas
[1] M. Gatzoulis,et al. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. , 2008, International journal of cardiology.
[2] B. Mulder,et al. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist? , 2007, American heart journal.
[3] P. Engelfriet,et al. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. , 2007, International journal of cardiology.
[4] K. Dimopoulos,et al. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease , 2007, Heart.
[5] B. Mulder,et al. Pulmonary arterial hypertension associated with a congenital heart defect: advanced medium-term medical treatment stabilizes clinical condition. , 2007, Congenital heart disease.
[6] P. Engelfriet,et al. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease , 2006, Heart.
[7] F. Fedele,et al. Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect , 2006, Heart.
[8] R. Speich,et al. Measurement of quality of life in pulmonary hypertension and its significance , 2006, European Respiratory Journal.
[9] D. Cokkinos,et al. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study , 2006, Heart.
[10] M. Humbert,et al. Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm. , 2006, Proceedings of the American Thoracic Society.
[11] R. Speich,et al. Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties. , 2006, Chest.
[12] M. Humbert,et al. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study , 2006, European Respiratory Journal.
[13] S. Hammerschmidt,et al. Long-Term Bosentan in Chronic Thromboembolic Pulmonary Hypertension , 2006, Respiration.
[14] B. Mulder,et al. Applicability of bosentan in Dutch patients with Eisenmenger syndrome: preliminary results on safety and exercise capacity. , 2006, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.
[15] T. Welte,et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. , 2005, Chest.
[16] W. Klepetko,et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. , 2005, Chest.
[17] D. Badesch,et al. Evaluation and Management of the Patient with Pulmonary Arterial Hypertension , 2005, Annals of Internal Medicine.
[18] D. Cokkinos,et al. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease , 2005, Heart.
[19] K. Kerr,et al. Chronic thromboembolic pulmonary hypertension. , 2004, Clinics in chest medicine.
[20] D. Mccrory,et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.
[21] R. Speich,et al. Clinical classification of pulmonary hypertension. , 2004, Journal of the American College of Cardiology.
[22] Paolo Prandoni,et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. , 2004, The New England journal of medicine.
[23] M. Uematsu,et al. Poor prognosis and related factors in adults with Eisenmenger syndrome. , 2002, American heart journal.
[24] K. Kerr,et al. Chronic thromboembolic pulmonary hypertension. , 2001, Clinics in chest medicine.
[25] D L Sherrill,et al. Reference equations for the six-minute walk in healthy adults. , 1998, American journal of respiratory and critical care medicine.
[26] J. Widimský,et al. Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. , 1982, Chest.
[27] M. Gatzoulis,et al. Double-Blind , Randomized , Placebo-Controlled Study Bosentan Therapy in Patients With Eisenmenger Syndrome : A Multicenter , 2006 .
[28] A. Waggoner,et al. Severe pulmonary hypertension without right ventricular failure: the unique hearts of patients with Eisenmenger syndrome. , 2002, The American journal of cardiology.
[29] D. Mccrory,et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.